Skip to main content

Table 2 Logistic regression for risk factors for adverse pathological outcomes

From: Free testosterone value before radical prostatectomy is related to oncologic outcomes and post-operative erectile function

Variables

pT3

Gleason 8 or higher

 

OR

95%CI

p value

OR

95%CI

p value

TT (normal vs low)

1.017

0.479–2.159

0.965

0.484

0.237–0.985

0.045*

FT (normal vs low)

0.587

0.374–0.921

0.020*

0.456

0.249-0.835

0.011*

Age (continuous)

1.006

0.979–1.034

0.665

1.006

0.979–1.003

0.677

BMI (continuous)

1.016

0.960–1.076

0.581

1.014

0.960–1.072

0.607

Diabetes (presence vs absence)

1.243

0.719–2.149

0.436

0.970

0.573–1.641

0.909

Hypertension (presence vs absence)

0.855

0.472–1.549

0.605

1.087

0.629–1.878

0.765

Coronary heart disease (presence vs absence)

1.203

0.624–2.322

0.581

1.279

0.683–2.395

0.443

Smoke (presence vs absence)

1.280

0.723–2.266

0.397

1.400

0.825–2.376

0.212

Alcohol (presence vs absence)

0.763

0.471–1.236

0.272

1.428

0.924–2.208

0.109

PSA (≥10 ng/ml vs < 10 ng/ml)

1.007

0.644–1.575

0.975

1.829

1.195–2.800

0.005*

Proportion of free-PSA (≥ 0.16 vs < 0.16)

0.851

0.540–1.340

0.486

1.030

0.664–1.599

0.894

Clinical Tumor stage (T2a vs T3)

0.057

0.021–0.153

< 0.001*

0.439

0.212-0.909

0.027*

Clinical (T2b vs T3)

0.059

0.029–0.120

< 0.001*

0.454

0.258-0.800

0.006*

Clinical (T2c vs T3)

0.474

0.299–0.750

0.001*

0.840

0.513-1.374

0.487

Biopsy Gleason Score (6 vs 8 or higher)

0.289

0.149–0.562

< 0.001*

0.179

0.093-0.344

< 0.001*

Biopsy Gleason Score (7 vs 8 or higher)

0.800

0.500–1.279

0.351

0.723

0.467–1.121

0.148

  1. OR odds ratio; CI confidence interval; TT total testosterone; FT free testosterone; PSA prostate-specific antigen; BMI body mass index; PSM positive surgical margin
  2. p value of less than 0.05 are in boldface
  3. *Statistically significant